submit news    HOME | FEEDBACK  


« NAVIGATION »
NEWS

- Bio/Medicine

- Chemicals

- Defense

- Drug Delivery

- Education

- Electronics

- Energy

- Events

- Grants

- Industry

- Investment

- Litigation

- Materials

- MEMS

- Nanofabrication

- Nanoparticles

- Nanotubes

- Optics

- Partnership

- Patent

- Products

- Quantum dots

- Research

- Smart Dust

- Software
COMPANIES
EVENTS

- Browse by Month

- Current Shows

- Previous Shows

- Submit Events
FEEDBACK
ADVERTISE
LINK TO US

« PARTNERS »
Become A Nanotechwire Partner

FEI Company

Veeco Instruments

Nano Science and Technology Institute

National Nanotechnology Initiative

Nanotechnology at Zyvex

Want to see your Company or Organization listed above? Become A Nanotechwire Partner Today - click here
« NEWSLETTER »



« SEARCH »







12/13/2010 11:00:16 AM
NanoLogix Cooperative Projects Update For EPA and University of Texas Health Science Center Houston

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announces the current 300 patient trial of NanoLogix GBS (Group B Streptococcus) Quick Tests is ongoing at the University of Texas Health Science Center (UTHSC) in Houston. NanoLogix anticipates initial filings for GBS Quick-Test FDA approval following final publication of the GBS trial results. In addition, this month UTHSC Houston plans to expand its evaluation of NanoLogix Quick Tests, concurrent with the GBS trial, to include the superbug MRSA (formally known as Methicillin-resistant Staphylococcus aureus), with E.Coli and Pseudomonas to follow in early 2011. For further information on the GBS trial please visit the UTHSC - Houston Newsroom at: http://www.uthouston.edu/media/newsreleases/nr2010/index.htm?id=2434326

NanoLogix Technology Focused on Domination of $150 Million U.S. Ob/Gyn GBS Testing Market

NanoLogix seeks to lead innovation in the market of GBS Ob/Gyn testing, which in the U.S. is valued at approximately $150 million annually. Initial results from UTHSC Houston last spring show the GBS Quick Tests returned reliable results in approximately four hours. With the current standard of 48-72 hours, this is a markedly significant reduction in testing time. Today’s GBS strains are resistant to ampicillin and amoxicillin and by improving standard detection speed, NanoLogix and the physicians at UTHSC Houston hope to dramatically reduce the overuse of antibiotics in pregnant women and contribute to the fight against GBS antibiotic resistance.

NanoLogix EPA CRADA To Continue Until 2012

NanoLogix is currently in the first phase of its work to assist the US Environmental Protection Agency (EPA) in the development of a comprehensive water quality test kit for use with surface and source waters. NanoLogix and the EPA have a Cooperative Research and Development Agreement (CRADA) with runs through 2012. For additional information please visit the internal news update archive at the EPA's Microbiological and Chemical Exposure Assessment Research Division (MCEARD): http://www.epa.gov/microbes/mceardnewsarchive.html

NanoLogix Cincinnati Laboratory

NanoLogix is pleased to announce an operations evolution in its BioStart Cincinnati laboratory designed to better serve the needs of its clients, customers, and partners. The company has added new equipment and appointed Ahmer Kodvowala, MS, MBA as Director of Laboratory Operations. Hilda Diaz, MS, will continue to serve as Senior Researcher. Joining the laboratory as the new research assistant is Michael Sube, BA. NanoLogix doubled the size of its laboratory facility in July 2010 and added additional office space at that time. The current changes are in keeping with established expansion plans.

Dr. Sergey Gazenko has left the company for personal reasons. He is the author of 2 of NanoLogix 34 granted patents and 3 patents pending. Dr. Gazenko will provide consulting services to NanoLogix as needed.

NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. Along with medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.

For more information visit http://www.nanologix.com.

Other Headlines from NanoLogix ...
 - Nanologix introduces new "Petri Flat Pack", to exhibit at American Society for Microbiology annual meeting in New Orleans and unveils new website
 - NanoLogix Cooperative Projects Update For EPA and University of Texas Health Science Center Houston
 - University of Texas Health Science Center Using NanoLogix Technology in 300 Patient Clinical Trial
 - NanoLogix Applauds Energy Bill Signing
 - NanoLogix Files Hydrogen Production Provisional Patent Application Expanding Its Intellectual Property Portfolio to 32 Patents Issued and Pending in Nanotechnology and NanoBiotechnology

More Partnership Headlines ...
 - FUJIFILM Joins SEMATECH’s Resist Center for Advanced EUV Resist Development at UAlbany NanoCollege
 - Luna Innovations and Hansen Medical Expand Development Work
 - IBM and SARA Sign Collaboration Agreement on Petascale Computing
 - APIC Corporation and UAlbany NanoCollege launch $10M partnership to develop and commercialize innovative 'green' computer chip technology
 - Crocus Technology Strikes $300 Million Financing Deal with RUSNANO to Build Advanced MRAM Manufacturing Facility in Russia


« Back To List »

« GET LISTED »
- submit company
- submit news
- submit events
- advertise here

« EVENTS »
- More Events


Copyright © 2017 Nanotechwire.com | Privacy Policy |